NeuBase Therapeutics, Inc. (NBSE) — Financial statements
Income statement, balance sheet, and cash flow for NeuBase Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 1↑119.4% | 0.58↑105.2% | 0.28↑118.5% | 0.13↓99.1% | 14 | |
| Gross Profit | -1↓119.4% | -0.58↓105.2% | -0.28↓118.5% | -0.13↑99.1% | -14 | |
| Operating Expenses | ||||||
| R&D Expenses | 21↑49.3% | 14↑106.8% | 7↓59.7% | 17↑299.2% | 4 | |
| General & Administrative Expenses | 12↓2.7% | 12↑20.5% | 10↑11.3% | 9↑150.3% | 4 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 12↓2.7% | 12↑20.5% | 10↑11.3% | 9↑150.3% | 4 | |
| Other Expenses | -0.17↓137.1% | 0.45↑9.2% | 0.41 | 0.00↓100.0% | 0.59 | |
| Operating Expenses | 33↑25.4% | 27↑55.6% | 17↓35.2% | 26↑190.1% | 9 | |
| Total Costs & Expenses | 33↑25.4% | 27↑55.6% | 17↓35.2% | 26↑190.1% | 9 | |
| Operating Results | ||||||
| Operating Income | -33↓25.4% | -27↓55.6% | -17↑35.2% | -26↓89.4% | -14 | |
| Depreciation & Amortization | 0.83↑29.2% | 0.64↑329.0% | 0.15↑16.5% | 0.13↓88.6% | 1 | |
| EBITDA | -33↓27.0% | -26↓50.5% | -17↑35.5% | -27↓753.6% | -3 | |
| EBIT | -34↓33.0% | -25↓46.0% | -17↑35.2% | -27↓2192.2% | -1 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.12↑729.5% | -0.02↓157.6% | -0.01↑94.0% | -0.13↓1550.7% | 0.01 | |
| Interest Income | 0.15↑1083.7% | 0.01↑163311.5% | 0.00↓94.0% | 0.00↓98.5% | 0.01 | |
| Interest Expense | 0.02↓25.6% | 0.03↑320.6% | 0.01↓94.0% | 0.13 | 0.00 | |
| Non-Operating Income | 0.43↑136.5% | -1↓486.5% | 0.31↓37.6% | 0.49↓27.1% | 0.68 | |
| Other Income / Expenses | -0.46↓139.6% | 1↑466.8% | -0.32↑49.3% | -0.62↑95.1% | -13 | |
| Income Before Tax | -34↓32.9% | -25↓46.2% | -17↑35.5% | -27↓103.7% | -13 | |
| Income Tax Expense | 0.46↑77.5% | 0.26↑309.4% | -0.12↓195.6% | 0.13↓98.6% | 9 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -34↓33.4% | -26↓48.7% | -17↑36.3% | -27↓104.6% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -34↓33.4% | -26↓48.7% | -17↑36.3% | -27↓104.6% | -13 | |
| Bottom-Line Net Income | -34↓33.4% | -26↓48.7% | -17↑36.3% | -27↓104.6% | -13 | |
| EPS (Basic) | -21.08↓12.1% | -18.80↓6.8% | -17.60↑73.1% | -65.49↑30.0% | -93.57 | |
| EPS (Diluted) | -21.08↓12.1% | -18.80↓6.8% | -17.60↑73.1% | -65.49↑30.0% | -93.57 | |
| Weighted Average Shares | 2↑19.0% | 1↑39.2% | 0.98↑137.2% | 0.41↑192.4% | 0.14 | |
| Weighted Average Diluted Shares | 2↑19.0% | 1↑39.2% | 0.98↑137.2% | 0.41↑192.4% | 0.14 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.